| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Get expert pediatric urgent care for your child. Find the KidMed location nearest you, or learn more about what makes us the regions leading choice.
At KBP we are consistently reminded that patient care is the end goal of what we do daily.
Through the use of telepsychiatry technology, we’re able to help our partner facilities see patients more efficiently and in a wide variety of locations.